Plasma levels of microparticles at 24 weeks of gestation do not predict subsequent pregnancy complications

Salomon, Ophira; Katz, Ben‐Zion; Dardik, Rima; Livnat, Tami; Steinberg, David M.; Achiron, R.; Seligsohn, Uri

doi:10.1016/j.fertnstert.2008.06.015

Cited by 11 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is currently a need to investigate women in the first trimester of pregnancy followed by serial blood sampling to determine whether endothelial MPs increase before the clinical symptoms of pre-eclampsia. Salomon et al have shown that the number of cell-derived MPs at 24 weeks of gestation does not have predictive value for the subsequent development of vascular diseases specific to pregnancy such as hypertension, preeclampsia, intrauterine growth restriction, and small-for-gestational age live births (111).…”

Section: Microparticles (Mps)mentioning

confidence: 99%

Endothelial dysfunction in the pathogenesis of pre-eclampsia

Szpera-Goździewicz

Bręborowicz

2014

Front Biosci

View full text Add to dashboard Cite

There are many theories regarding the ultimate cause of pre-eclampsia, and nowadays it is thought that the mechanism of pathogenesis is most likely multifactorial. The pathophysiology probably involves both fetal or placental and maternal factors. The most likely relevant factors in the pathogenesis are the abnormal development of the placenta, systemic endothelial dysfunction or cell activation, and an imbalance between pro-angiogenic and anti-angiogenic proteins with a predominance of anti-angiogenic factors. In women with pre-eclampsia, placental tissue overproduces two main anti-angiogenic proteins which enter into the maternal circulation: soluble Fms- such as tyrosine kinase 1 (sFlt1 or sVEGFR1) and soluble endoglin (sEng). Moreover, these patients have low circulating blood levels of two pro-angiogenic peptides: placental growth factor (PlGF) and vascular endothelial growth factor (VEGF). Adequate levels of CECs (circulating endothelial cells), EPCs (endothelial progenitor cells) and microparticles most likely play an important part in the development and regulation of vascularization in pregnancy but the exact role of these cells and micropatticles in the pathogenesis of pre-eclampsia is unknown. Some imbalances in these levels are associated with endothelial insufficiency.

show abstract

Section: Microparticles (Mps)mentioning

confidence: 99%

Endothelial dysfunction in the pathogenesis of pre-eclampsia

Szpera-Goździewicz

Bręborowicz

2014

Front Biosci

View full text Add to dashboard Cite

show abstract

“…Total EV concentrations were measured in 76 studies. Results from 56 of these were included in our analysis as the other twenty studies did not report their vesicle concentrations as /mL or /μL of starting material (Cui et al., 2021; Desprez et al., 2008; Elfeky et al., 2017; Ezrin et al., 2015; Franzago et al., 2021; Freeman et al., 2008; Holthe et al., 2005; Jørgensen et al., 2020; Levine et al., 2020; Meziani et al., 2008; Motawi et al., 2018; Rajaratnam et al., 2021; Sabapatha et al., 2006; Salomon et al., 2009; Sarker et al., 2014; Tan et al., 2014, 2017; Tesse et al., 2007; Uszyński et al., 2013). The results from non‐pregnant, healthy pregnant and pathological pregnant cohorts are summarised in Figure 5a.…”

Section: Resultsmentioning

confidence: 99%

Circulating extracellular vesicles in healthy and pathological pregnancies: A scoping review of methodology, rigour and results

Barnes,

Pantazi,

Holder

2023

J of Extracellular Vesicle

View full text Add to dashboard Cite

Extracellular vesicles (EVs) play a crucial role in pregnancy, revealed by the presence of placental‐derived EVs in maternal blood, their in vitro functionality, and their altered cargo in pregnancy pathologies. These EVs are thought to be involved in the development of pregnancy pathologies, such as pre‐eclampsia, pre‐term birth, and fetal growth restriction, and have been suggested as a source of biomarkers for gestational diseases. However, to accurately interpret their function and biomarker potential, it is necessary to critically evaluate the EV isolation and characterization methodologies used in pregnant cohorts. In this systematic scoping review, we collated the results from 152 studies that have investigated EVs in the blood of pregnant women, and provide a detailed analysis of the EV isolation and characterization methodologies used. Our findings indicate an overall increase in EV concentrations in pregnant compared to non‐pregnant individuals, an increased EV count as gestation progresses, and an increased EV count in some pregnancy pathologies. We highlight the need for improved standardization of methodology, greater focus on gestational changes in EV concentrations, and further investigations into the functionality of EVs. Our review suggests that EVs hold great promise as diagnostic and translational tools for gestational diseases. However, to fully realize their potential, it is crucial to improve the standardization and reliability of EV isolation and characterization methodologies, and to gain a better understanding of their functional roles in pregnancy pathologies.

show abstract

“…The studies were published between 2002 and 2019 and included a total number of 1885 patients (862 with PE and 1023 with healthy pregnancy). 3 articles 9,11,20 included 540 patients (96 with PE and 444 with healthy pregnancy) measured MPs in the second trimester. 21 articles 6-8, 10, 12-19, 22-30 included 1310 patients (748 with PE and 562 with healthy pregnancy) in the third trimester and 4 articles 14,15,21,24 included 233 patients (118 with PE and 115 with healthy pregnancy) in the postpartum.…”

Section: Characteristics Of Studiesmentioning

confidence: 99%

“…Three studies 9,11,20 reported microparticles in the second trimester, of which one study reported tMPs 11 , two studies reported EMPs 9,20 and one studies reported PMPs 20 . There was no significant difference in all types of microparticles (SMD: 0.34, 95% CI: -0.36 to 1.04, I 2 =91%, P = 0.34) between PE and healthy pregnant patients (Figure 2).…”

Section: Outcomes In the Second Trimestermentioning

confidence: 99%

Microparticles in Preeclampsia during Pregnancy: A Systematic Review and Meta-analysis

McClements

Guo

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Preeclampsia (PE) is a severe manifestation of maternal hypertensive disease with high morbidity and mortality which microparticles (MPs) might be generated. But there is limited evidence on response MPs with PE. Objectives: To explore the relationship between MPs and PE. Search strategy: A systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines in Pubmed, Embase, Web of Science and China National Knowledge Infrastructure (inception to September 20, 2022). Selection criteria: Studies on patients diagnosed as PE were included. Studies on patients with chronic hypertension, pre-gestational diabetes mellitus, and history of recurrent pregnancy loss, renal or hepatic diseases, and antiphospholipid syndrome were excluded. Data collection and analysis: Two authors independently screened the studies, extracted the data and assessed the quality of the studies. Results were combined descriptively and analyzed using a standardized Excel form. Main results: We included 25 studies with a total of 1885 patients (862 with PE and 1023 with healthy pregnancy). Any MPs level was found no significant difference between PE and healthy pregnant patients in the second trimester. However, CD31-marked EMPs, RMPs and MPs from placenta are significantly elevated in the third trimester of preeclampsia, while CD41-marked PMPs is significantly decreased. After postpartum, tMPs and EMPs were found no significant difference between PE and healthy pregnant patients. Conclusion: MPs level is significantly associated with PE in the third trimester, but the association is dependent on its cell source and labeled marker.

show abstract

Plasma levels of microparticles at 24 weeks of gestation do not predict subsequent pregnancy complications

Cited by 11 publications

References 19 publications

Endothelial dysfunction in the pathogenesis of pre-eclampsia

Endothelial dysfunction in the pathogenesis of pre-eclampsia

Circulating extracellular vesicles in healthy and pathological pregnancies: A scoping review of methodology, rigour and results

Microparticles in Preeclampsia during Pregnancy: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About